In the phase-3 studies from the EDITION clinical registration program [11–14], Gla-300 proved to be non-inferior to Gla-100 in T1D and T2D patients as well as among insulin naïve patients or switchers. This evidence concerns the gene INS and type 2 diabetes mellitus.